These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 17964711)
21. Optical platelet aggregometry does not appear useful as a means of assessing the risk of recurrent vascular events in aspirin-treated patients. Sztriha LK; Sas K; Seres E; Boda K; Lenti L; Csifcsak G; Kovacs N; Vecsei L Acta Neurol Scand; 2008 Apr; 117(4):250-4. PubMed ID: 17961197 [TBL] [Abstract][Full Text] [Related]
22. Incidence of aspirin resistance and its relationship with cardiovascular risk factors and graft function in renal transplant recipients. Acikel S; Yildirir A; Aydinalp A; Demirtas K; Bal U; Kaynar G; Ozin B; Karakayali H; Muderrisoglu H; Haberal M Transplant Proc; 2008 Dec; 40(10):3485-8. PubMed ID: 19100419 [TBL] [Abstract][Full Text] [Related]
23. Screening for aspirin resistance in stable coronary artery patients by three different tests. Chakroun T; Addad F; Abderazek F; Ben-Farhat M; Hamdi S; Gamra H; Hassine M; Ben-Hamda K; Samama MM; Elalamy I Thromb Res; 2007; 121(3):413-8. PubMed ID: 17553552 [TBL] [Abstract][Full Text] [Related]
24. Prevalence of aspirin resistance measured by PFA-100. Coma-Canella I; Velasco A; Castano S Int J Cardiol; 2005 May; 101(1):71-6. PubMed ID: 15860386 [TBL] [Abstract][Full Text] [Related]
25. Triflusal and aspirin have different effects on inflammatory biomarkers measured in patients with acute ischemic stroke. Alvarez-Sabín J; Penalba A; Quintana M; Krupinski J; García-Bonilla L; Montaner J Cerebrovasc Dis; 2009; 28(4):371-7. PubMed ID: 19641312 [TBL] [Abstract][Full Text] [Related]
26. The clinical importance of laboratory-defined aspirin resistance in patients presenting with non-ST elevation acute coronary syndromes. Acikel S; Yildirir A; Aydinalp A; Bal U; Kaynar G; Ozin B; Muderrisoglu H Blood Coagul Fibrinolysis; 2009 Sep; 20(6):427-32. PubMed ID: 19542882 [TBL] [Abstract][Full Text] [Related]
27. Aspirin non-responder status and early neurological deterioration: a prospective study. Bugnicourt JM; Roussel B; Garcia PY; Canaple S; Lamy C; Godefroy O Clin Neurol Neurosurg; 2011 Apr; 113(3):196-201. PubMed ID: 21145162 [TBL] [Abstract][Full Text] [Related]
28. The effectiveness of antiplatelet treatment with aspirin in polymorbid patients. Paluch Z; Jedlicková V; Skibova J; Adamek T; Alusík S Int Angiol; 2007 Sep; 26(3):206-12. PubMed ID: 17622200 [TBL] [Abstract][Full Text] [Related]
29. Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use. Reaume KT; Regal RE; Dorsch MP Ann Pharmacother; 2008 Apr; 42(4):550-7. PubMed ID: 18319394 [TBL] [Abstract][Full Text] [Related]
30. Predictors of high platelet reactivity during aspirin treatment in patients with type 2 diabetes. Kapłon-Cieślicka A; Rosiak M; Postuła M; Serafin A; Kondracka A; Opolski G; Filipiak KJ Kardiol Pol; 2013; 71(9):893-902. PubMed ID: 24065375 [TBL] [Abstract][Full Text] [Related]
31. Sex difference in the antiplatelet effect of aspirin in patients with stroke. Cavallari LH; Helgason CM; Brace LD; Viana MA; Nutescu EA Ann Pharmacother; 2006 May; 40(5):812-7. PubMed ID: 16608908 [TBL] [Abstract][Full Text] [Related]
33. [Incidence of aspirin resistance in the patient group of a university hospital in Korea]. Lee YK; Kim HS; Park JY; Kang HJ Korean J Lab Med; 2008 Aug; 28(4):251-7. PubMed ID: 18728372 [TBL] [Abstract][Full Text] [Related]
34. [Use of assessment of aggregation of thrombocytes induced by cationic propyl gallate to estimate recurrence of cardiovascular complications]. Stejskal D; Prosková J; Lacnák B; Horalík D; Hamplová A; Oral I; Hrabovská I; Ochmanová R; Adamovská S; Juráková R; Ozanová G; Juchelka J; Kulísková O; Pĕnkavová H Vnitr Lek; 2004 Aug; 50(8):591-9. PubMed ID: 15521202 [TBL] [Abstract][Full Text] [Related]
35. Lack of association between aspirin responsiveness and seven candidate gene haplotypes in patients with symptomatic vascular disease. Kunicki TJ; Williams SA; Nugent DJ; Harrison P; Segal HC; Syed A; Rothwell PM Thromb Haemost; 2009 Jan; 101(1):123-33. PubMed ID: 19132198 [TBL] [Abstract][Full Text] [Related]
37. The Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) study: baseline characteristics of the population. Bousser MG; Amarenco P; Chamorro A; Fisher M; Ford I; Fox K; Hennerici M; Mattle HP; Rothwell PM; Cerebrovasc Dis; 2009; 27(6):608-13. PubMed ID: 19407444 [TBL] [Abstract][Full Text] [Related]
38. Pathophysiologic, rather than laboratory-defined resistance drives aspirin failure in ischemic stroke. Agayeva N; Gungor L; Topcuoglu MA; Arsava EM J Stroke Cerebrovasc Dis; 2015 Apr; 24(4):745-50. PubMed ID: 25680657 [TBL] [Abstract][Full Text] [Related]
39. Aspirin response evaluated by the VerifyNow Aspirin System and light transmission aggregometry. Nielsen HL; Kristensen SD; Thygesen SS; Mortensen J; Pedersen SB; Grove EL; Hvas AM Thromb Res; 2008; 123(2):267-73. PubMed ID: 18499236 [TBL] [Abstract][Full Text] [Related]
40. Aspirin resistance and adverse clinical events in patients with coronary artery disease. Chen WH; Cheng X; Lee PY; Ng W; Kwok JY; Tse HF; Lau CP Am J Med; 2007 Jul; 120(7):631-5. PubMed ID: 17602938 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]